LENZ Therapeutics, Inc. - Common Stock LENZ 深 滬
已收盤 09-19 16:00:00 美东时间
42.27
+0.580
+1.39%
華盛通- 最 高44.00
- 今 開42.37
- 成交量 92.93万股
- 最 低 41.50
- 昨 收 41.69
- 總市值 11.90亿
- 52周最高 44.00
- 市盈率 靜 --
- 換手率 3.30%
- 52周最低 16.535
- 委 比 -71.43%
- 總股本 2814.62万
- 歷史最高 230.79
- 量 比 2.70
- 振 幅 6.00%
- 歷史最低 3.92
- 每 手 1
- 風險率 5.48%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多H.C. Wainwright Reaffirms Their Buy Rating on LENZ Therapeutics (LENZ)
In a report released today, Matthew Caufield from H.C. Wainwright reiterated a ...
08-22 19:25
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers IO Biotech (NASDAQ:IOBT) stock rose 52.5% to $2.76 during Monday's pre...
08-11 20:08
Why International Money Express Shares Are Trading Higher By Around 54%; Here Are 20 Stocks Moving Premarket
Shares of International Money Express, Inc. (NASDAQ:IMXI) rose sharply in pre-m...
08-11 17:22
美股大行评级 | 花旗、小摩分别上调苹果目标价；瑞穗上调Robinhood目标价从99美元升至120美元
今日重点评级关注：花旗：维持Apellis Pharmaceuticals"买入"评级，目标价从46美元升至52美元；BTIG：维持Strategy"买入"评级，目标价从620美元升至700美元
08-04 09:30
美股大行评级 | 罕见！Meta、微软连续获多家大行上调目标价；花旗上调Robinhood目标价升至120美元
今日重点评级关注：丰业银行：维持Arcellx"跑赢大市"评级，目标价从93美元升至133美元；RBC Capital：维持Precision Drilling"跑赢大市"评级，目标价从89美元升至100美元
08-01 10:17
LENZ Therapeutics Announces US FDA Approval of VIZZ™ for the Treatment of Presbyopia
VIZZ, the first FDA-approved aceclidine-based eye drop for treating presbyopia, improves near vision for up to 10 hours with once-daily use. LENZ Therapeutics announced its approval, with samples expected in the U.S. as early as October 2025 and broader availability by mid-Q4 2025. VIZZ's unique mechanism contracts the iris sphincter, creating a pinhole effect without myopic shift. Clinical trials demonstrated significant near vision improvement ...
07-31 20:05
Lenz Therapeutics Prepares for LNZ100 Launch
Lenz Therapeutics, Inc. ( ($LENZ) ) has released its Q2 earnings. Here is a bre...
07-31 14:53
LENZ Therapeutics Q2 EPS $(0.53) Beats $(0.62) Estimate, Sales $5.000M Beat $4.181M Estimate
LENZ Therapeutics (NASDAQ:LENZ) reported quarterly losses of $(0.53) per share which beat the analyst consensus estimate of $(0.62) by 14.52 percent. This is a 32.5 percent decrease over losses of $(0.40) per share from
07-30 20:11
LENZ Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
LENZ Therapeutics reported its NDA for LNZ100, an aceclidine-based eye drop for presbyopia, remains on track for an August 8, 2025 PDUFA decision. The company has hired an 88-member sales force and secured over $195 million in upfront and milestone payments through international licensing agreements. Cash reserves of $209.6 million as of June 30, 2025 are expected to support operations to post-launch profitability.
07-30 12:00
HC Wainwright & Co. Maintains Buy on LENZ Therapeutics, Raises Price Target to $48
HC Wainwright & Co. analyst Matthew Caufield maintains LENZ Therapeutics (NASDAQ:LENZ) with a Buy and raises the price target from $38 to $48.
07-28 18:15
